ViroCarb is a pharmaceutical company developing antiviral drugs. They have discovered a new class of small molecules that inhibit the replication of pathogenic viruses by targeting the host (e.g., humans) cell functions used by pathogenic viruses to grow and multiply. ViroCarb’s preclinical drug candidate, GPS-491 has shown to block the replication of multiple viral families including HIV, Adenoviruses, and Coronaviruses in human cells.